Sutro Biopharma, Inc. (STRO) Stock

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

Sutro Biopharma, Inc. is led by CEO Jane Chung, employs 269 people, headquartered in US, publicly traded since 2018.

Sutro Biopharma, Inc. (STRO) stock trades at $9.33 with a market capitalization of $154.70M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.84, reflecting a net loss over the last twelve months, a negative price-to-book of -2.35, reflecting negative shareholders' equity, price-to-sales of 3.10. Over the past 52 weeks the stock has ranged between $7.15 and $43.85, and currently trades 78.7% below its 52-week high.

On profitability, Sutro Biopharma, Inc. generates a return on equity (ROE) of 185.30% (not meaningful, as shareholders' equity is negative), return on capital employed of -106.06%, an operating margin of -102.94%, a net profit margin of -395.25%.

Official website: www.sutrobio.com

Sutro Biopharma, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Sutro Biopharma, Inc. reported revenue of $60.0M rising to $102.0M, a change of +70.0% across 10 years. Compounded, revenue has grown 18.9% a year over five years, 14.5% over three, 64.5% over the last twelve months. Net profit fell to $-191.0M.

Operating margin went from 2.3% in 2016 to -102.4% in 2025, a fall of 104.7 percentage points. The most recent net margin is -395.25%. On a trailing twelve-month basis to Jun '26, revenue is $47.0M and net profit $-181.0M.

Borrowings rose from $1.0M to $16.0M, cash on hand is $54.0M, cash from operations was $-177.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged -105.6% over five years, and was 144.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Sutro Biopharma, Inc. (STRO) — frequently asked questions